Disease · MONDO_0008219

pemphigus vulgaris

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pemphigus vulgaris. Diseases, record MONDO_0008219. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008219

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pemphigus vulgaris; Open Targets
Open Targets ID: MONDO_0008219; Open Targets
Other names: PV; Open Targets
Disease Ontology: DOID:0060851; Disease Ontology
MeSH: C536645; MeSH
NCI Thesaurus: C34910; NCI Thesaurus
Orphanet: ORPHA:704; Orphanet
Highest stage of its drugs: Approval, for 3 of its 24 drugs, from DailyMed; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov and TTD	4	3	3	Drugs and targets
EFGARTIGIMOD ALFA	CHEMBL4297551	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Phase 3	ClinicalTrials.gov and TTD	3	2	2	Drugs and targets
RILZABRUTINIB	CHEMBL3702854	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
OFATUMUMAB	CHEMBL1201836	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AZATHIOPRINE	CHEMBL1542	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	6	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
FCGRT	IgG receptor FcRn large subunit p51	2	IgG receptor FcRn large subunit p51 antagonist	Phase 3	https://conductscience.org/library/genes/2217	Drugs and targets
INSR	Insulin receptor	2	Insulin receptor agonist	Phase 2	https://conductscience.org/library/genes/3643	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
TNF	Tumor necrosis factor	2	TNF-alpha inhibitor	Phase 2	https://conductscience.org/library/genes/7124	Drugs and targets
BTK	Tyrosine-protein kinase BTK	1	Tyrosine-protein kinase BTK inhibitor	Phase 3	https://conductscience.org/library/genes/695	Drugs and targets
IL2RA	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 2	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 2	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 2	https://conductscience.org/library/genes/3561	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials24

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04598451	A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	Phase 3	222	2024-10-01	Pemphigus Vulgaris, Pemphigus Foliaceus	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT04598477	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	Phase 3	183	2025-03-30	Pemphigus Vulgaris, Pemphigus Foliaceus	EFGARTIGIMOD ALFA	Its record names the disease	ClinicalTrials.gov
NCT02383589	A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)	Phase 3	135	2020-01-18	Pemphigus Vulgaris	MYCOPHENOLATE MOFETIL, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03762265	A Study of PRN1008 in Patients With Pemphigus	Phase 3	131	2022-09-21	Pemphigus	RILZABRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT00683930	A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)	Phase 3	96	2011-06-22	Pemphigus Vulgaris (PV)	MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT02704429	A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris	Phase 2	42	2023-02-13	Pemphigus Vulgaris	RILZABRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT01920477	Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris	Phase 3	35	2019-06-06	Pemphigus Vulgaris	OFATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00283712	Use of Infliximab for the Treatment of Pemphigus Vulgaris	Phase 2	20	2013-01-31	Pemphigus	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01930175	Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris	Phase 2	13	2020-10-19	Pemphigus Vulgaris	IANALUMAB	Its record names the disease	ClinicalTrials.gov
NCT00286325	Rituximab in the Treatment of Patients With Bullous Pemphigoid	Phase 1/2	8	2012-10-22	Bullous Pemphigoid	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 24

See all 24 trials

Comparisons in its trials22

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy Within 30 Weeks	55 of 147	24 of 75	222	NCT04598451	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: deaths from any cause	0 of 147	0 of 75	222	NCT04598451	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: serious adverse events	18 of 147	10 of 75	222	NCT04598451	Trial comparisons
Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy	44 of 124	20 of 66	190	NCT04598451	Trial comparisons
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin	55 of 101	26 of 48	149	NCT04598477	Trial comparisons
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Rate of Treatment Failure in Participants With PV and PF	3 of 101	1 of 48	149	NCT04598477	Trial comparisons
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: deaths from any cause	0 of 101	1 of 48	149	NCT04598477	Trial comparisons
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: serious adverse events	16 of 101	4 of 48	149	NCT04598477	Trial comparisons
Efgartigimod-efgartigimod PH20 SC vs Placebo-efgartigimod PH20 SC: Proportion of Participants With Pemphigus Vulgaris (PV) Who Achieve CRmin	47 of 86	22 of 41	127	NCT04598477	Trial comparisons
Part A vs Part B: deaths from any cause	0 of 27	0 of 15	42	NCT02704429	Trial comparisons

1 to 10 of 22

See all 22 comparisons in its trials

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25123295	RESULT	1	PubMed
16702494	RESULT	1	PubMed
42723554	DERIVED	1	PubMed
35663943	DERIVED	1	PubMed
34608631	DERIVED	1	PubMed
34126109	DERIVED	1	PubMed
34097368	DERIVED	1	PubMed
20410913	DERIVED	1	PubMed
18209165	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008219

GET https://conductscience.org/api/diseases/v1/MONDO_0008219/drugs?page=2

API reference For AI assistants